A Phase I Study of Veliparib (ABT-888) in Combination With Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWAR) in Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis With Two Additional Dose Levels in Patients With Epithelial Ovarian, Fallopian or Primary Peritoneal Cancers and Intra-abdominal Disease
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Veliparib (Primary)
- Indications Cancer metastases; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions
- 18 Jan 2017 Status changed from active, no longer recruiting to completed, according to final results published in the Gynecologic Oncology Journal.
- 18 Jan 2017 Final results published in the Gynecologic Oncology Journal.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology